期刊
HLA
卷 98, 期 4, 页码 357-365出版社
WILEY
DOI: 10.1111/tan.14374
关键词
isoforms; ovarian carcinoma; progression; sHLA-G
资金
- Ministry of Higher Education and Scientific Research
The study found that levels of sHLA-G and sHLA-G1 were significantly elevated in ovarian carcinoma patients, with high levels of sHLA-G molecules associated with older age, advanced stage, lymph node metastasis, and distant metastasis. Additionally, sHLA-G monomers were also significantly increased in ovarian carcinoma patients. These findings suggest that HLA-G could serve as a potential biomarker for advanced and complicated ovarian carcinoma, with implications for disease progression and recurrence assessment.
HLA-G is a non-classical major histocompatibility complex class Ib molecule. Its expression has been described in various cancer types, including ovarian cancer. HLA-G molecule has been implicated in immune escape and in progression of ovarian tumor cells. Our goal was to assess if total soluble (s)HLA-G molecules or HLA-G5 and sHLA-G1 isoforms could be considered as circulating ovarian tumor biomarkers, we measured the concentration of these molecules in ovarian carcinoma patients stratified according with their clinicopathological parameters. sHLA-G, sHLA-G1 and HLA-G5 concentrations were dosed in plasma samples by sandwich-ELISA. The sHLA-G dimerization was analyzed after immunoprecipitation and SDS-PAGE migration. Total sHLA-G and sHLA-G1 levels were significantly represented in plasma of ovarian carcinoma patients compared to healthy controls. sHLA-G1 isoform concentration was highly represented in ovarian carcinoma compared to HLA-G5 isoforms. Additionally, high sHLA-G molecules have been found in aged patients, as well as in patients with advanced stages, and those with metastatic lymph nodes and those with distant metastasis. Elsewhere, sHLA-G monomers were highly represented in ovarian carcinoma patients compared to controls. sHLA-G plasmatic protein was highly represented in ovarian carcinoma. In effect, HLA-G might be considered as a new checkpoint molecule that could be used to assess progression and recurrence of the disease, thus placing it as a potential biomarker for advanced and complicated ovarian carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据